### **Appendix 3B**

#### New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12

Name of entity

#### KINGSTON RESOURCES LIMITED

ABN

44 009 148 529

We (the entity) give ASX the following information.

#### Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1	<sup>+</sup> Class of <sup>+</sup> securities issued or to be issued	Unlisted Options Performance Rights
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	72,819,561 Unlisted Options 24,273,187 Performance Rights
3	Principal terms of the +securities (eg, if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)	<ol> <li>Unlisted Options exercisable at \$0.001/expiry 31 July 2023</li> <li>Unquoted STI Performance Rights granted to employees and executive director subject to performance and vesting conditions being satisfied before 31 July 2020</li> </ol>

+ See chapter 19 for defined terms.

4	<ul> <li>Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?</li> <li>If the additional securities do not rank equally, please state: <ul> <li>the date from which they do</li> <li>the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul> </li> </ul>	<ul> <li>1)No – upon exercise of the Options into fully paid shares they will rank equally with KSN shares</li> <li>2)No – upon vesting of the Performance Rights into fully paid shares they will rank equally with KSN shares</li> </ul>
5	Issue price or consideration	Nil
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Options and Performance Rights granted to employees and executive director
6a	Is the entity an <sup>+</sup> eligible entity that has obtained security holder approval under rule 7.1A?	Yes
	If Yes, complete sections 6b – 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i	
6b	The date the security holder resolution under rule 7.1A was passed	6 November 2019
60	Number of +securities issued	NI/A
6с	without security holder approval under rule 7.1	N/A
6d	Number of +securities issued	N/A
ou	without security holder approval under rule 7.1A	

- Number of +securities issued 6e with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)
- Number of securities issued 6f under an exception in rule 7.2
- If securities issued under rule 6g 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.
- 6h If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements
- Calculate the entity's remaining 6i issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements
- Dates of entering +securities 7 into uncertificated holdings or despatch of certificates

8 Number and +class of all +securities quoted on ASX (including the securities in section 2 if applicable)

Number	+Class
Ordinary Shares	
1,765,920,584	KSN

A	

See Annexure 1

6 November 2019

N/A

N/A

N/A

N/A

		Number	+Class
9	Number and <sup>+</sup> class of all <sup>+</sup> securities not quoted on ASX ( <i>including</i> the securities in section 2 if applicable)	5,000,000 Options (Expiry 22/12/19, Ex 2.5 cents)	KSNLTUO4
		30,375,909 Options (Expiry 30/6/2021, Ex 2.7 cents)	KSNLTU06
		4,000,000 Options (Expiry 31/12/20, Ex 0.1 cent)	KSNSTU01
		3,695,625 Performance Rights (Expiry 30/06/2020 -	KSNLTPR2
		subject to Performance and Vesting Conditions)	
		8,577,740 Performance Rights (Expiry 30/06/2021 – subject to Performance and Vesting Conditions)	KSNLTPR3
		16,549,431 Performance Rights (Expiry 30/6/2022 – subject to Performance and Vesting Conditions)	KSNLTPR4
		1,500,000 Performance Rights (Expiry 8/4/21 – subject to vesting conditions)	KSNLTPR5
		New	
		24,273,187 Performance Rights (Expiry 31/7/20 – subject to vesting conditions)	KSNSTPR5
		72,819,561 Options (Expiry 31/7/23; Ex 0.1 cent)	KSNLTUO7
10	Dividend policy (in the case of a trust distribution policy) on the	N/A	

trust, distribution policy) on the increased capital (interests)

### Part 2 - Bonus issue or pro rata issue

holder approval N/A 11 Is security required?

12	Is the issue renounceable or non- renounceable?	N/A
13	Ratio in which the <sup>+</sup> securities will be offered	N/A
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates	N/A
15	<sup>+</sup> Record date to determine entitlements	N/A
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
17	Policy for deciding entitlements in relation to fractions	N/A
18	Names of countries in which the entity has <sup>+</sup> security holders who will not be sent new issue documents Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.	N/A
19	Closing date for receipt of acceptances or renunciations	N/A
20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of <sup>+</sup> security holders	N/A

<sup>+</sup> See chapter 19 for defined terms.

25	If the issue is contingent on <sup>+</sup> security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do <sup>+</sup> security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do <sup>+</sup> security holders sell <i>part</i> of their entitlements through a broker and accept the balance?	N/A
32	How do <sup>+</sup> security holders dispose of their entitlements (except by sale through a broker)?	N/A
33	<sup>+</sup> Despatch date	N/A

#### Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

34	Type of securities
	(tick one)

(b)

(a) Securities described in Part 1

All other securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

#### Entities that have ticked box 34(a)

#### Additional securities forming a new class of securities

*Tick to indicate you are providing the information or documents* 

35 If the \*securities are \*equity securities, the names of the 20 largest holders of the additional \*securities, and the number and percentage of additional \*securities held by those holders

To be provided.

36	If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories
	1 - 1,000
	1,001 - 5,000
	5,001 - 10,000
	10,001 - 100,000
	100,001 and over
	To be provided.

A copy of any trust deed for the additional <sup>+</sup>securities

#### Entities that have ticked box 34(b)

37

38	Number of securities for which <sup>+</sup> quotation is sought	N/A
39	Class of <sup>+</sup> securities for which quotation is sought	N/A
40	<ul> <li>Do the <sup>+</sup>securities rank equally in all respects from the date of allotment with an existing <sup>+</sup>class of quoted <sup>+</sup>securities?</li> <li>If the additional securities do not rank equally, please state: <ul> <li>the date from which they do</li> <li>the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul> </li> </ul>	N/A

<sup>+</sup> See chapter 19 for defined terms.

Reason for request for quotation N/A 41 now

> Example: In the case of restricted securities, end of restriction period

> (if issued upon conversion of another security, clearly identify that other security)

Number and <sup>+</sup>class of all 42 +securities quoted on ASX (including the securities in clause 38)

Number	+Class

#### **Quotation agreement**

- <sup>+</sup>Ouotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX 1 may quote the +securities on any conditions it decides.
- We warrant the following to ASX. 2
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those +securities should not be granted +quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
- If we are a trust, we warrant that no person has the right to return the \*securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any 3 claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any 4 information or document not available now, will give it to ASX before <sup>+</sup>quotation of the <sup>+</sup>securities begins. We acknowledge that ASX is relying on

the information and documents. We warrant that they are (will be) true and complete.



2019

(Company secretary)

Print name: Rozanna Lee

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3B – Annexure 1

# Calculation of placement capacity under rule 7.1 and rule 7.1A for \*eligible entities

Introduced 01/08/12

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
<i>Insert</i> number of fully paid ordinary securities on issue 12 months before date of issue or agreement to issue	1,223,198,383	
<ul> <li>Add the following:</li> <li>Number of fully paid ordinary securities issued in that 12 month period under an exception in rule 7.2</li> <li>Number of fully paid ordinary securities issued in that 12 month period with shareholder approval</li> <li>Number of partly paid ordinary securities that became fully paid in that 12 month period</li> <li>Note:</li> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	<ul> <li>3,023,694 ordinary shares issued on 25/7/19 upon partial vesting of STI Performance Rights (KSNST4) issued to Executive Director on 9/11/18 – approval by shareholders at AGM on 8/11/18) – remainder have lapsed</li> <li>58,666,858 ordinary shares issued on 5/6/19 (pro rata non-renounceable rights issue announced to shareholders on 3/5/19)</li> <li>192,793,865 ordinary shares issued on 19/8/19 (remaining shortfall from pro rata non-renounceable rights issue announced to shareholders on 3/5/19)</li> <li>213,186,388 placement shares issued under 7.1 capacity on 8/10 May 2019 - ratified by shareholders on 6/11/19</li> <li>72,376,112 placement of shares on 8 and 10 May 2019 - 7.1A capacity refreshed at AGM on 6/11/19 -</li> </ul>	
<b>Subtract</b> the number of fully paid ordinary securities cancelled during that 12-month period	N/A	
" <b>A</b> "	1,763,245,300	

Step 2: Calculate 15% of "A"	
"B"	0.15

	[Note: this val	lue cannot be changed]
<i>Multiply</i> "A" by 0.15	264,486,795	
Step 3: Calculate "C", the amount of that has already been used	of placemen	t capacity under rule 7.7
<ul> <li>Insert number of equity securities issued or agreed to be issued in that 12-month period not counting those issued:</li> <li>Under an exception in rule 7.2</li> <li>Under rule 7.1A</li> <li>With security holder approval under rule 7.1 or rule 7.4</li> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> <li>"C"</li> </ul>	2,675,284 4,000,000 12,867,978 19,543,262 <b>3"] to calcul</b>	(Ordinary Shares issued on 25/7/19 upon partial vesting of FY19 STI Performance Rights (KSNPRST4) remainder have lapsed) (STI Options issued to employees on 6/6/19) (KSNLTU01) (FY20 STI Performance Rights issued to employees on 6/11/19)
<i>placement capacity under rule 7.1</i> "A" x 0.15	264,486,795	
Note: number must be same as shown in Step 2		
Subtract "C"	19,543,262	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.15] – "C"	244,943,533	
	[Note: this is t capacity unde	the remaining placement er rule 7.1]

<sup>+</sup> See chapter 19 for defined terms.

Rule 7.1A – Additional placement capacity for eligible entities				
Step 1: Calculate "A", the base figure from which the placement capacity is calculated				
<b>"A"</b> Note: number must be same as shown in Step 1 of Part 1	1,763,245,300			
Step 2: Calculate 10% of "A"				
"D"	0.10 Note: this value cannot be changed			
<i>Multiply</i> "A" by 0.10	176,324,530			
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used				
<i>Insert</i> number of equity securities issued or agreed to be issued in that 12-month period under rule 7.1A	Nil			
<ul> <li>Notes:</li> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>				
"E"	Nil			

## Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A

"A" x 0.10 Note: number must be same as shown in Step 2	176,324,530
<b>Subtract</b> "E" Note: number must be same as shown in Step 3	Nil
<i>Total</i> ["A" x 0.10] – "E"	<b>176,324,530</b> Note: this is the remaining placement capacity under rule 7.1A